New Hair Loss Treatment Clinical Trials

London, United Kingdom, February 25, 2010 --(PR.com)-- The thinning hair experts from the UK - Nanogen are planning to be involved in no less than 4 clinical trials in 3 countries, involving both the increasingly popular Scalproller device and other cutting edge therapeutic techniques.

Nanogen widens their scope for hair loss treatment, becoming involved with large scale clinical trials for the extremely promising Platelet Rich Plasma treatment. Platelet Rich Plasma therapy received much applause when early results found it could not only improve hair growth and survival of transplanted hair, but also re-grew hair in a patient with Alopecia Areata. Nanogen hopes to be able to reinforce these early findings with larger trials, and contribute to newer growth-factor hair loss treatments. Other trials with Nanogen’s hair growth maintenance range are planned but details are not yet available.

Aside from research with existing products, Nanogen is collaborating with the University of Bonn to produce an accurate genetic test for hair loss, and has an exclusive agreement with researchers in Bonn to use chromosome 20 as the basis for a test to predict hair loss, as well as accurately diagnose Androgenetic Alopecia patients.

The company also plans to further bolster their professional background with the formation of a dedicated Expert Panel of hair transplant surgeons, trichologists, dermatologists and even grooming experts to advise and contribute to current and future hair loss research.

Nanogen will continue their ambitious programme of research throughout the New Year and beyond. For more information on Nanogen’s products and hair loss research please visit www.nanogen.org.

###

Editor’s Notes:
Nanogen is a trademarked brand of Pangaea Laboratories Ltd. Founded in 1999 by pharmacologist Elliot Isaacs, Pangaea has always maintained high standards of scientific research, and all their products are developed with the aim of delivering cutting edge cosmetic technology to the public. This release was written by Toby Cobbledick, for any further information, please contact toby@pangaea.co.uk or +44 (0)20 8458 2500